Tivozanib (AV-951): Selective Pan-VEGFR Inhibitor for Oncology Research

Executive Summary: Tivozanib (AV-951) is a highly selective second-generation tyrosine kinase inhibitor (TKI) that targets VEGFR-1, VEGFR-2, and VEGFR-3 with picomolar potency, showing an IC50 of 160 pM for VEGFR-2 in biochemical assays (Schwartz 2022). It exhibits minimal off-target inhibition, including low c-KIT activity, and demonstrates significant in vivo antitumor effects in renal cell carcinoma (RCC) models. Clinically, Tivozanib achieves a progression-free survival (PFS) of 12.7 months in RCC patients when administered orally at 1.5 mg/day for 3 weeks. The compound is a quinoline-urea derivative with high solubility in DMSO and is recommended for short-term solution use at -20°C. Its synergy with EGFR-targeted agents enhances apoptosis and growth inhibition in preclinical ovarian carcinoma models.

Biological Rationale

Angiogenesis is a hallmark of tumor progression and is primarily driven by the vascular endothelial growth factor (VEGF) signaling axis. VEGFR-1, VEGFR-2, and VEGFR-3 are key mediators of this pathway, regulating endothelial cell proliferation, migration, and survival. Inhibition of VEGFR tyrosine kinase activity disrupts neovascularization, limiting nutrient supply and tumor expansion (Schwartz 2022). Pan-VEGFR inhibitors, such as Tivozanib, block all three VEGFRs, providing a broad anti-angiogenic effect. Compared to first-generation multitargeted TKIs, second-generation agents like Tivozanib offer higher selectivity and reduced off-target toxicity.

Mechanism of Action of Tivozanib (AV-951)

Tivozanib (AV-951) is a quinoline-urea compound that binds the ATP-binding site of VEGFR-1, VEGFR-2, and VEGFR-3 tyrosine kinases. It inhibits VEGFR-2 with an IC50 of 160 pM, and also blocks phosphorylation of PDGFRß and c-KIT at nanomolar concentrations in cellular assays (ApexBio). This high potency translates to effective suppression of downstream angiogenic signaling, including reduced endothelial cell proliferation and migration. Tivozanib's selectivity profile minimizes inhibition of non-VEGFR kinases, notably c-KIT, thus lowering the risk of hematologic toxicities compared to broader-spectrum TKIs. In cell-based models, 10 μM Tivozanib for 48 hours induces significant growth inhibition and apoptosis, especially when combined with EGFR-targeted therapies. The oral bioavailability and favorable pharmacokinetics support once-daily dosing in clinical regimens.

Evidence & Benchmarks

• Tivozanib inhibits VEGFR-2 kinase activity with an IC50 of 160 pM in biochemical assays (Schwartz 2022, Fig. 2.1).
• Demonstrates minimal c-KIT inhibition at therapeutic concentrations, reducing off-target effects (ApexBio).
• In RCC xenograft models, Tivozanib shows marked tumor growth inhibition compared to vehicle and sunitinib controls (Schwartz 2022, Table 3.2).
• Shows synergistic effects with EGFR-targeted therapies in ovarian carcinoma cell lines, enhancing apoptosis and growth arrest (Schwartz 2022, Sec. 5.4).
• Clinically, Tivozanib achieves a median progression-free survival (PFS) of 12.7 months in metastatic RCC in Phase III trials (Schwartz 2022, Clinical Data).
• Exhibits superior VEGFR-2 inhibition potency compared to sunitinib, sorafenib, and pazopanib in head-to-head in vitro assays (Schwartz 2022, Comparative Analysis).

This article extends the mechanistic and workflow-specific insights from "Tivozanib (AV-951): Mechanistic Insight and Strategic Guidance" by providing atomic, directly benchmarked claims and up-to-date clinical parameters. For advanced in vitro modeling and application in physiologically relevant settings, see "Tivozanib (AV-951): Precision VEGFR Inhibition in Dynamic Models", which focuses on microenvironment-specific responses.

Applications, Limits & Misconceptions

Tivozanib (AV-951) is primarily used in preclinical and clinical workflows for the investigation and treatment of solid tumors driven by angiogenic signaling, with a strong focus on renal cell carcinoma. In vitro, it is applied at 10 μM for 48-hour exposures in cell viability and apoptosis assays. Its high selectivity and low off-target profile make it suitable as a reference standard in VEGFR signaling pathway studies. However, its water insolubility necessitates formulation in DMSO or ethanol, with prompt use of prepared solutions to avoid degradation. Combination strategies with EGFR inhibitors are supported by robust preclinical data in ovarian carcinoma models. Tivozanib is not recommended for tumors lacking VEGFR pathway activation or for use in models highly sensitive to c-KIT inhibition.

Common Pitfalls or Misconceptions

• Tivozanib is not broadly cytotoxic; it relies on VEGFR pathway activation for efficacy and is ineffective in VEGFR-independent tumors.
• Long-term storage of Tivozanib solutions is discouraged due to compound instability; use freshly prepared DMSO/ethanol solutions.
• It is not a suitable substitute for multitargeted TKIs in settings where broad kinase inhibition (e.g., PDGFR, c-KIT) is therapeutically required.
• Combination synergy with EGFR inhibitors is cell-type dependent and not observed in all carcinoma models (Schwartz 2022).
• Water-insolubility limits its use in aqueous-only systems without organic cosolvents.

Workflow Integration & Parameters

For in vitro studies, Tivozanib is dissolved at ≥22.75 mg/mL in DMSO or ≥2.68 mg/mL in ethanol with gentle warming (ApexBio). Recommended working concentrations are 10 μM, applied for 48 hours in cell-based assays. Storage at -20°C is advised; solutions should not be stored long-term. In clinical research, oral administration at 1.5 mg once daily for 3 weeks is standard for RCC patients. Tivozanib can be integrated into anti-angiogenic screening panels or used in combination protocols targeting both VEGFR and EGFR pathways. As a reference pan-VEGFR inhibitor, it is frequently employed in mechanistic pathway dissection studies and competitive benchmarking against first-generation TKIs, such as sunitinib, sorafenib, and pazopanib.

Conclusion & Outlook

Tivozanib (AV-951) remains a gold-standard, highly selective VEGFR inhibitor for oncology research and clinical applications. Its potency, favorable safety profile, and validated efficacy in RCC support its continued use as both a therapeutic and methodological benchmark. Future research may further elucidate its role in combinatorial therapy and resistance modeling. For detailed product specifications or to obtain the A2251 kit, visit the Tivozanib (AV-951) product page.